Meeting
2019 ASCO Annual Meeting
A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).
Authors
Teresa Macarulla Mercade
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain
Teresa Macarulla Mercade , Victor Moreno , Binu John , John Charles Morris , Michael B. Sawyer , Wei Peng Yong , Martin Gutierrez , Thomas Benjamin Karasic , Bruno Sangro , Yang Sheng-Shun , Carleen Gentry , Amy Kim , Pavan Kumar , Crystal MacKenzie , Nathalie Rioux , Joanne Schindler , Anand Selvaraj , Richard S. Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02834780
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4095)
DOI
10.1200/JCO.2019.37.15_suppl.4095
Abstract #
4095
Poster Bd #
200
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
First Author: Teresa Macarulla
Poster
2022 ASCO Annual Meeting
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
First Author: Patricia LoRusso
Poster
2021 ASCO Annual Meeting
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
First Author: Alison M. Schram
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit